Brief: Elevation Oncology Announces First Patient Dosed In The Phase 1 Clinical Trial Evaluating EO-3021
16/08/2023 12:42
Aug 16 (Reuters) - Elevation Oncology Inc ELEV.O :
* ELEVATION ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE 1
CLINICAL TRIAL EVALUATING EO-3021
* ELEVATION ONCOLOGY INC - EXPECT TO REPORT PRELIMINARY DATA
ON
SAFETY AND ANTI-TUMOR ACTIVITY FROM OUR PHASE 1 STUDY DURING
FIRST HALF OF 2025
Source text for Eikon: ID:nPn6Mf6hga
Further company coverage: ELEV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elevation Oncology
See all newsBrief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
U.S. RESEARCH ROUNDUP- Crane, Ryder System, Terex
Brief: Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing